Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.
Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.
Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.
Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.
Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.
Hologic (Nasdaq: HOLX) has announced its participation in two upcoming investor conferences. The company will present at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on May 29th at 10 a.m. CT. Additionally, Hologic will present at the William Blair 44th Annual Growth Stock Conference in Chicago, Illinois on June 4th at 8:40 a.m. CT. Both presentations will be webcast live and available for 30 days on the company’s investor relations website.
Hologic, Inc. (Nasdaq: HOLX) announced Q2 fiscal 2024 results, with revenue of $1,017.8M, GAAP EPS $0.72, Non-GAAP EPS $1.03, exceeding guidance. Total company organic revenue growth was 4.9% in constant currency. The company raised full-year revenue midpoint and EPS guidance.
Hologic, Inc. (Nasdaq: HOLX) announced the acquisition of Endomagnetics for $310 million, enhancing their breast surgery portfolio with innovative technologies. The deal is expected to expand options for breast cancer procedures, increase global access to advanced solutions, and improve patient care. Endomag's revenue in 2023 was approximately $35 million. The acquisition will be slightly dilutive to Hologic's non-GAAP earnings per share in 2024, break even in 2025, and accretive thereafter.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
What does Hologic Inc. specialize in?
Where is Hologic Inc. headquartered?
What are the main segments of Hologic’s business?
Which segment contributes the most to Hologic's revenue?
How has the pandemic affected Hologic’s business segments?
What percentage of Hologic’s revenue comes from the United States?
How did the acquisition of Gen-Probe impact Hologic?
How can I stay updated with Hologic's latest news?
What is Hologic’s approach to healthcare?
What percentage of Hologic’s revenue comes from international markets?
